Drugs that block muscarinic receptors are able to enhance nerve repair in various diseases of the peripheral nervous system. In collaboration with WinSanTor Inc based in San Diego, USA, the laboratory of Dr. Paul Fernyhough at University of Manitoba now plans to develop novel peptide antagonists that also block the muscarinic receptor. These peptides will provide new intellectual property and permit testing of efficacy to prevent disease in animal models of neuropathy.
Join a thriving innovation ecosystem. Subscribe now